SLN
Silence TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that divesiran is the primary asset the market cares about and the company has already de-risked execution somewhat by finishing SANRECO enrollment ahead of schedule, with 3Q 2026 topline data now the key unlock [#PR-2025-10-23][#PR-2026-03-05].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -1.7.
What can break
AstraZeneca notified Silence on March 4, 2026 that it will not pursue further SLN312 development beyond Phase 1, reducing one external validation path.
Momentum
51
Value
54
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $11.00 · Bear $3.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $32.80
Why
Momentum51 · Δ7d +4.0
Value54 · Δ7d +0.0
Sentiment54 · Δ7d -1.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
51
34% active weight
Current posture
7d trendImproving
Δ7d
+4.0
Δ21d
-34.8
Value
54
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.3
Sentiment
54
33% active weight
Current posture
7d trendSoftening
Δ7d
-1.7
Δ21d
+17.0
Why this grade
Composite grade C. Momentum 51.2 / Value 54.1 / Sentiment 54.5
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$300.88M
Beta
0.56
Shares Out
141.7M
P/E (TTM) · Derived
-2.2
P/S (TTM)
10.85
P/FCF (TTM)
6.91
Rev YoY
-89.3%
EPS YoY
+40.6%
Gross Margin
+91.2%
Op Margin
-326.4%
Net Debt
-$147.33M
Current Ratio
7.69
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology